ABSTRACT

The term “mastocytosis” denotes a heterogeneous group of disorders characterised by abnormal growth and accumulation of mast cells (MC) in one or more organ systems. Symptoms result from MC chemical mediator’s release, pathologic infiltration of neoplastic MC in tissues or both. Multiple molecular, genetic and chromosomal defects seem to contribute to an autonomous growth, but somatic c-kit D816V mutation is more frequently encountered, especially in systemic disease.

We present a literature review of mastocytosis and a rare case report of an 18 month-old-girl with a bullous dermatosis, respiratory distress and anaphylaxis, as clinical manifestations of mastocytosis.

The developments of accepted classification systems and novel useful markers allowed a re-evaluation and updating of the classification of mastocytosis. In paediatric age cutaneous forms of disease prevail and may regress spontaneously. SM is more frequently diagnosed in adults and is a persistent (clonal) disease of bone marrow. The clinical course in these patients is variable.

Today diagnostic criteria for each disease variant are reasonably well defined. There are, however, peculiarities, namely in paediatric age, that makes the diagnostic approach difficult. Systemic disease may pose differential diagnostic problems resulting from multiple organ systems involvement. Conversely, the “unexplained” appearance of those symptoms with no skin lesions should raise the suspicion of MC disease.

This case is reported in order to stress the clinical severity and difficult diagnostic approach that paediatric mastocytosis may assume.


INTRODUCTION

In 1869, Nettleship and Tay first described the typical mastocytosis lesions (urticaria pigmentosa) as a rare form of urticaria.1 Soon after the discovery of mast cells (MC), by Paul Ehrlich in 1879, these lesions were found to contain focal accumulations of MC.2 However, it was not until 1949 that Ellis described the systemic variant of the disease with involvement of visceral organs.3

DEFINITION

The term “mastocytosis” denotes a heterogeneous group of disorders characterised by abnormal growth and accumulation of MC in one or more organ systems. It is also described as a neoplastic disease involving MC and their progenitors CD34+.4
EPIDEMIOLOGY

Current estimates on prevalence of mastocytosis range from 1 in 1000 to 8000 patients in the dermatology office. In children approximately 5.4 cases per 1000 children are treated in dermatological clinics. Rosenthal et al estimated that there are two new cases per year in a population of 300,000 corresponding to an incidence of 0.00667%. Mastocytosis occurs equally in both sexes and as been described in different ethnic groups, although there are more reports in caucasians.

PATHOPHYSIOLOGY

MC are haematopoietic cells that reside in vascularized tissues, namely the connective tissues, often in the vicinity of smaller or larger blood vessels or nerve fibres. They are derived from multipotent hematopoietic progenitors CD34+, detectable in bone marrow as well as peripheral blood. Subsequently they distribute in the blood and transmigrate through the endothelial barrier into tissues before undergoing terminal differentiation and maturation.

During differentiation MC acquire distinct morphologic and phenotypic properties with four defined stages of maturation: the non-granulated (tryptase-positive) blast cell; the metachromatic blast cell; the promastocyte/atypical MC type II and the mature MC. Several cytokines and the local microenvironment are considered to contribute to mastopoeisis. A pivotal cytokine in this process, the principle MC growth factor, is the Stem Cell (SCF) or kit-ligand. The effects of SCF on MC and their progenitors are mediated through a specific MC’s receptor – transmembrane tyrosine kinase receptor, KIT or CD117.

The MC produce and release a variety of clinically relevant mediators and immunoregulatory mediators including histamine, heparin and cytokines are stored. Several are released in response to aggregation of the high affinity IgE receptor, activation through complement receptors or activation by cytokines. Others, such as tryptase, are both constitutively secreted from MC and released after its activation. Two tryptase genes (α and β) are expressed by human MC. α-(pro)tryp-tase is secreted constantly from the cell and its levels reflect the total tryptase baseline, which appear to correlate with the MC number. β-tryp-tase is stored in MC granules and levels are found to be elevated after MC activation, such as anaphylaxis, and are usually otherwise undetectable. Total serum tryptase levels are a reliable non-invasive diagnostic approach to estimate the burden of MC in patients with mastocytosis and allow the distinction between categories of disease. In healthy individuals an average Sng/ml is found (< 15 ng/ml).

Symptoms in mastocytosis result from MC-derived mediators and, less frequently, from destructive infiltration of MC [skin, bone marrow, gastrointestinal tract, skeletal, central nervous system (CNS) or lymphoreticular system (spleen, liver and lymph nodes)]. The MC produce and release a variety of clinically relevant mediators such as histamine, leukotrienes, proteases or heparin (table I). Depending on the type of MC involved, burden of MC, course of disease and co-existing disorders, these mediators may be released to a variable degree resulting in different clinical patterns. In some of these patients the symptoms are mild and may not require therapy, in others, they are severe and potentially fatal (urticaria, recurrent flushing, dyspnoea, chest pain, bleeding tendency, peptic ulcer, abdominal pain, severe bone pain, headache, recurrent syncope and hypotensive shock).

Organ infiltration may occur: without organ dysfunction (B-findings); with impaired organ function (C-findings) or organ failure (table II).

Allergol et Immunopathol 2008;36(3):154-63
On the basis of recent advances in mastocytosis research, an updated consensus classification for mastocytosis was proposed in 2001 and subsequently adopted by the WHO (table III). The proposed classification is based on formulated criteria. In this concept cutaneous mastocytosis (CM) is based on clinical (urticaria pigmentosa, Darier’s sign, mastocytoma) and histological findings (multifocal or diffuse infiltrates of MC) together with the absence of criteria that would allow the diagnosis of SM. SM criteria are divided into major criteria (histological and immunohistochemical) and minor criteria (typical cytomorphological and novel biochemical markers) listed in table IV.

The existence of one major and one minor criterion or two minor criteria establish the diagnosis of SM.41

CLINICAL FEATURES

The occurrence of mastocytosis is usually sporadic. Familial mastocytosis (AD) is a very rare condition with only 50 families recorded in the literature since 1880.22 In up to 15 % of patients the disease is congenital.35

Approximately 65 % of individuals with mastocytosis present with disease in childhood; 55 % of these have manifestations of disease by the age of two. The remaining 35 % that develop the symptoms after puberty are classified as adult onset.36

Most pediatric cases of mastocytosis are asymptomatic or minimally symptomatic with spontaneous resolution during or after adolescence (50 %).42 Around 90 % of these patients have isolated cutaneous symptoms, while 10 % have systemic involvement.43 It is, therefore, a benign condition.44

Urticaria pigmentosa (UP) is the most common variant of CM.45 It usually presents as red-brown macules and papules, often with symmetrical distribution and even anaphylactic reaction after mechanical/thermal stimulation of skin lesions.46 In contrast, dermographism is characterised by the appearance of the same lesions after stroking or scratching normal appearing skin. Three rare subvariants of UP have been proposed based on distinct clinical aspects: plaque form, a nodular form and a telangiectatic (Telangiectasia Macularis Eruptiva Persistans – TMEP). The younger the patient and the smaller the number of the lesions the higher the probability of spontaneous remission.10

The occurrence of mastocytosis is usually sporadic. Familial mastocytosis (AD) is a very rare condition with only 50 families recorded in the literature since 1880.22 In up to 15 % of patients the disease is congenital.22

Approximately 65 % of individuals with mastocytosis present with disease in childhood; 55 % of these have manifestations of disease by the age of two. The remaining 35 % that develop the symptoms after puberty are classified as adult onset.36

Most pediatric cases of mastocytosis are asymptomatic or minimally symptomatic with spontaneous resolution during or after adolescence (50 %).42

Around 90 % of these patients have isolated cutaneous symptoms, while 10 % have systemic involvement.43 It is, therefore, a benign condition.44

Urticaria pigmentosa (UP) is the most common variant of CM.45 It usually presents as red-brown macules and papules, often with symmetrical distribution and even anaphylactic reaction after mechanical/thermal stimulation of skin lesions.46 In contrast, dermographism is characterised by the appearance of the same lesions after stroking or scratching normal appearing skin. Three rare subvariants of UP have been proposed based on distinct clinical aspects: plaque form, a nodular form and a telangiectatic form (Telangiectasia Macularis Eruptiva Persistans – TMEP). The younger the patient and the smaller the number of the lesions the higher the probability of spontaneous remission.10

Bullous mastocytosis or Diffuse CM is a very rare and severe variant of CM which usually occurs in the first year of life.44 It is characterised by intensely itchy, generalised yellowish, thickened skin with doughy/leathery feel and the appearance of large blisters, sometimes haemorrhagic, spontaneously or following mild trauma due to diffuse MC infiltration.45,46

Children with more extensive skin involvement are more likely to exhibit systemic symptoms: flushing, headache, palpitations, abdominal pain, diarrhoea, dyspnoea, wheezing, syncope, hy-
potent shock and death. Early onset of blisters worsens the prognosis. It is also associated with an increased risk of progression to MCL. The mastocytoma of the skin presents as a macular, papular or nodular (< 1cm) lesion of yellow, brown or reddish colour. It rarely evolves into SM-AHNMD.

Patients with adult onset mastocytosis generally have evidence of systemic disease (SM). It can follow a benign/indolent course as a persistent clonal disorder (disorder of the bone marrow) or it may be associated with life-threatening haematologic disorders. SM includes four major subtypes: indolent SM (ISM); SM associated with non-mast cell clonal haematological disease (SM-AHNMD); aggressive SM (ASM); and MC Leukemia (MCL). ISM represents 2/3 of all cases of SM and shows a prolonged clinical course (survival time of two decades or more). SM-AHNMD combines two completely different histologies: the MC lineage and non-MC lineage (myelodysplastic syndrome, myeloproliferative syndrome, acute myeloid leukemia, Non-Hodgkin’s lymphoma). The haematological disease associated is most frequently (80-90 %) of myeloid lineage. The type of haematologic disorder associated deter-

Table II

<table>
<thead>
<tr>
<th>B-findings</th>
<th>C-findings*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) High MC burden:</td>
<td>C-findings: impaired organ function due to infiltration by neoplastic MC.</td>
</tr>
<tr>
<td>Infiltration grade MC of b.m. &gt; 30%</td>
<td>Severe progressive pancytopenia, ANC &lt; 1000/μl.</td>
</tr>
<tr>
<td>(histology) and serum</td>
<td>Transfusion dependence, Pt &lt; 20 000/μl.</td>
</tr>
<tr>
<td>tryptase &gt; 200 ng/ml</td>
<td>Progressive deterioration of liver function, loss of appropriate protein synthesis, hepatic coma, severe coagulation disorder</td>
</tr>
<tr>
<td>2) Dysmyelopoiesis:</td>
<td></td>
</tr>
<tr>
<td>hypercellular marrow; loss of fat cells; myelodysplasia or myeloproliferative; normal blood counts or slight persisting deviation without progression</td>
<td></td>
</tr>
<tr>
<td>3) Organomegaly:</td>
<td></td>
</tr>
<tr>
<td>palpable hepatomegaly</td>
<td></td>
</tr>
<tr>
<td>without ascitis or other signs of organ impairment and/or lymphadenopathy (palpable or visceral LN enlargement found in US or CT &gt; 2cm) and/or palpable splenomegaly (without hypersplenism)</td>
<td></td>
</tr>
</tbody>
</table>

b.m: bone marrow; ANC: absolute neutrophile count; Pt: platelets; LN: lymph node; US: ultrasound; CT: computer tomography.

Adapted from Valent et al.

Table III

<table>
<thead>
<tr>
<th>WHO classification of Mastocytosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variants and subvariants</td>
</tr>
<tr>
<td>-----------------------------------</td>
</tr>
<tr>
<td>Cutaneous Mastocytosis</td>
</tr>
<tr>
<td>Maculopapular CM</td>
</tr>
<tr>
<td>Diffuse or Bulbous CM</td>
</tr>
<tr>
<td>Cutaneous Mastocytoma</td>
</tr>
<tr>
<td>Indolent Systemic Mastocytosis</td>
</tr>
<tr>
<td>Smouldering SM</td>
</tr>
<tr>
<td>Isolated bone marrow Mastocytosis</td>
</tr>
<tr>
<td>Systemic Mastocytosis with an Associated clonal haematologic non-MC lineage disease</td>
</tr>
<tr>
<td>Aggressive Systemic Mastocytosis</td>
</tr>
<tr>
<td>with Lymphadenopathy (AML)</td>
</tr>
<tr>
<td>MC Leukemia</td>
</tr>
<tr>
<td>Aleukemic MCL</td>
</tr>
<tr>
<td>MC Sarcoma</td>
</tr>
</tbody>
</table>

*Also termed clonal pigmentation.

**The subtype of AHNMD has to be defined by WHO criteria as well.

In these patients circulating MC are less than 10 %.

Adapted from Valent et al.
mines its prognosis. It is, therefore, important to accurately determine the type of SM in these patients. ASM is characterised by progressive infiltration of various organs with function impairment (severe cytopenias, malabsorption, bone fractures, peripheral eosinophilia, and hepatopathy) but usually without typical skin lesions. The clinical course is variable. MCL is characterized by leukemic infiltration of various organs by immature neoplastic MC. The prognosis is often poor. Localised MC proliferations are extremely rare and include both Extrapcutaneous Mastocytoma and MC Sarcoma. Mastocytoma is a benign tumour with uniformal growth, low grade cytology and good prognosis. MC Sarcoma is a local destructive tumour, usually with poor prognosis.

Patients with SM should be followed-up to monitor the development of any signs of disease progression or evolution to AHNMD.
total body volume and total volume of skin, compared with adults. Therefore, consideration should be given to monitoring the serum tryptase level over time and to not perform a bone marrow puncture unless there are suggesting signs of systemic disease.

The existence of more than 15 MC per aggregate (diffuse or multifocal infiltrates with a significant percentage of spindle-shape cells) fulfils the diagnosis of SM. If the majority of MC are round it is necessary to investigate additional criteria because such accumulations have been detected in reactive MC hyperplasia (parasite infections, neoplastic disorders, aplastic anemia, and chronic inflammatory diseases), SCF-treated patients and myeloid leukemia without mastocytosis. However, one should be alert to the possibility of MC disease when patients present “inexplicable” symptoms that might be related with MC-mediator release such as vascular instability, anaphylactic shock, flushing, diarrhoea and headache, even if no skin lesions are found.

**DIFFERENTIAL DIAGNOSIS**

SM symptoms, in the absence of skin lesions, are often non-specific and thus confused with other underlying conditions namely: endocrine (adrenal tumour, gastrinoma, VIPoma, carcinoid syndrome), cardiovascular (idiopathic anaphylaxis, cardiac disease, aortic stenosis, vasculitis, essential hypertension), gastrointestinal (peptic ulcer, ulcerative colitis, hepatitis, parasite disease, gluten-sensitive enteropathy), pulmonary, allergic, infectious, immunologic, rheumatologic and oncologic. However, one should be alert to the possibility of MC disease when patients present “inexplicable” symptoms that might be related with MC-mediator release such as vascular instability, anaphylactic shock, flushing, diarrhoea and headache, even if no skin lesions are found.

**TREATMENT**

It is consensual, since no curative therapies are available, that mastocytosis should be treated according to the symptoms presented. In patients with predominant mediator-release symptoms, “mediator-targeting” drugs must be prescribed in addition to avoidance of triggers of MC degranulation (table VII). Commonly used medication includes anti-histamines (H1/H2), MC stabilisers, acetylsalicylic acid (aspirin), ketotifen or adrenaline. Aspirin is used for flushing, tachycardia and syncope. Ketotifen has been recommended for bone pain and/or flushing. Gastric ulcerative disease requires the use of H2 anti-histamines or a proton pump inhibitor.

---

**Table VI**

<table>
<thead>
<tr>
<th>Initial sign/symptom</th>
<th>Recommended diagnostic procedures</th>
</tr>
</thead>
</table>
| UP-like skin lesions (paediatric patients) | 1. Skin biopsy (with analysis of c-kit D816V) + serum tryptase (monitoring)  
2. Bone marrow investigation in cases with suspected hematologic disease/SM |
| UP-like skin lesions (adult patients) | 1. Bone marrow examination + skin biopsy + serum tryptase (>20 ng/ml in most cases)  
2. In case of MS - complete staging |
| Reported mediator symptoms but no skin lesions (UP) | 1. Serum tryptase, if >20 ng/ml – 2  
2. Bone marrow examination, if SM – 3  
3. SM – staging |
| Severe unexplained allergic reaction/Anaphylaxis at presentation | 1. Serum tryptase, if >20 ng/ml – 2  
2. Repeat serum tryptase a few weeks later, if serum tryptase >20 ng/ml – 3  
3. Bone marrow examination, if SM – 4  
4. SM-staging |

a In young infants, a serum tryptase slightly exceeding 20 ng/ml is not regarded as a safe indicator for SM. Therefore, it is recommended to wait and to monitor the serum tryptase level over time in these patients.

b Complete staging: gastrointestinal tract, skeleton (X-ray, scintigraphy), abdomen US, complete blood count, serum chemistry, coagulation, c-kit mutations.

c Especially in patients with aggressive MC disorders, skin lesions are absent. Therefore, it is of pivotal importance to know the subtype of SM in these patients as soon as possible. In ASM serum tryptase level is usually higher than in patients with isolated bone marrow mastocytosis (often <20 ng/ml), a benign MC disease in which skin lesions are also absent.

Adapted from Valent et al.
many patients a combination of H1 and H2 anti-histamines is administered. Low dose of corticosteroids may relieve malabsorption and ascitis. Self administered epinephrine is indicated in recurrent anaphylac-

Allergol et Immunopathol 2008;36(3):154-63
cytoreductive drugs are recommended: with or without corticosteroids, or cladribine. If no fusion gene and others (excluding the c-kit mutation) are associated to gene defects such as the FIP1L1-PDGFRA rearrangement (FDA) that might be useful in SM (ASM) only such drug approved by the Food and Drug Administration. Clinical trials are being conducted with potential drug targets in neoplastic MC. Investigation is focused on the identification of molecular/genetic markers and potential drug targets in neoplastic MC. Investigation is addressed to targeted-drugs such as: tyrosine kinase inhibitors (imatinib mesilate, AMN107, desatinib, PKC412), non tyrosine kinase kit signalling inhibitors (imidazoles, bortezomib, rapamycin) and monoclonal antibodies (denileukine diftitox, gemtuzumab ozogamicin). Imatinib mesilate is currently the only such drug approved by the Food and Drug Administration (FDA) that might be useful in SM (ASM) associated to gene defects such as the FIP1L1-PDGFRα fusion gene and others (excluding the c-kit mutation of DB16V).

Preliminary data of a study conducted by Carter et al demonstrates that anti-IgE therapy (omalizumab) may have efficacy in preventing anaphylaxis in patients with SM resulting from reduction of MC survival and overaccumulation.

CASE REPORT

We present a case report of an 18 month-year-old, caucasian girl. She had a dystocic birth at 37 weeks and neonatal hypoxic-ischemic encephalopathy with hypotension. She was a child of non-consanguineal parents and with maternal history of atopic dermatitis and latex allergy.

At four months of age the child exhibited a pruriginous microvesicular rash of the neck. It was diagnosed as atopic dermatitis and treated accordingly. However, there was a progressive worsening, showing extension of skin lesions to the trunk. Six months later she developed an erythematous rash of the face and trunk followed by respiratory distress and respiratory arrest and syncope. The child’s mother gave her a cold bath with immediate recovery. She was treated with intravenous corticosteroid and oral anti-histamine in the emergency department. Apparently there was no prior episode of fever, cold symptoms, insect stings, trauma, sudden/intense temperature changes or histamine-release food/drink ingestion. Less than 24 hours after hospital discharge, a bullous dermatosis with transparent fluid of the face, neck and trunk started along with dyspnoea. She was taken to the hospital and remained admitted for 2 weeks, showing total remission under treatment with adrenaline, oral and topical corticosteroids, hydroxyzine, ketotifen and fluoclocycline. The skin biopsy confirmed the diagnosis of mastocytosis.

Laboratory work-up showed raised levels of serum tryptase (381 ng/ml) and total IgE (1138 KU/L). The absence of persistent significant levels of serum tryptase, organomegalies and skeletal or peripheral blood anomalies eliminated the indication for bone marrow biopsypuncture.

No further anaphylactic episodes occurred. However, daily episodes of flushing and urticaria elicited by heat, pressure and friction are noticed even under regular treatment with cetirizine, dissodic chloromycyclate, ketotifen and avoidance of trigger factors of MC mediator-release.

There were no side effects of therapy nor a need for use of self-administered epinephrine prescribed.

Physical examination revealed urticarial skin lesions in areas that suffered pressure, resulting from child’s handling. The remaining skin had a normal aspect and texture.

The c-kit mutation research is in progress.
CONCLUSIONS

During the last few years, major advances in mastocytosis research have been made. Thus, by using defined criteria it is now possible to discriminate between MC disorders and other systemic diseases.

Mastocytosis is a relatively rare disorder, but its diagnosis is of relevance because of the multiple clinical manifestations and due to the risk of associated symptoms.

Although pediatric mastocytosis is usually benign, sometimes it can be clinically exuberant or severe and with a difficult diagnostic approach. Multidisciplinary work is therefore essential in order to diagnose, treat and manage the disease.

ACKNOWLEDGMENTS

The authors would like to thank to Dr. Orquídea Silva I et al.—MASTOCYTOSIS: A RARE CASE OF ANAPHYLAXIS IN PAEDIATRIC AGE AND LITERATURE REVIEW
47. Silveira I et al.—MASTOCYTOSIS: A RARE CASE OF ANAPHYLAXIS IN PAEDIATRIC AGE AND LITERATURE REVIEW
62. Fung et al.—MASTOCYTOSIS: A RARE CASE OF ANAPHYLAXIS IN PAEDIATRIC AGE AND LITERATURE REVIEW